Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 15/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286406 | 0.97 | SLC10A2 (0.37) | SLC10A2RAB9ANR1H4FAAHCYP2C19 | |
| SCHEMBL14559698 | 0.92 | SLC10A2 (0.38) | SLC10A2RAB9ANR1H4 | |
| SCHEMBL3806800 | 0.92 | SLC10A2 (0.38) | SLC10A2RAB9ANR1H4 | |
| SCHEMBL22286643 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL5223154 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL22286487 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL30611635 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL30540746 | 0.92 | SLC10A2 (0.43) | SLC10A2NR1H4 | |
| SCHEMBL22286483 | 0.91 | SLC10A2 (0.39) | SLC10A2RAB9ANR1H4FAAHCYP2C19 | |
| SCHEMBL6633251 | 0.90 | SLC10A2 (0.41) | SLC10A2RAB9ANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | Aibireo AB (SE) | 2021-04-13 | — | — | US | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885RAB9A 1661/4885NR1H4 6/4885 |
| US-10975045-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885RAB9A 1661/4885NR1H4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.